Русский
Comparative characteristics of the incidence of various endocrinopathies in cancer patients receiving treatment with immune checkpoint inhibitors
DOI: https://dx.doi.org/10.18565/pharmateca.2024.2.50-54
Zhurtova I.B., Aramisova L.S., Abdul Moati H.A., Arkhestova D.R., Khachmakhova E.Z.
Department of Faculty Therapy, Medical Academy, Kabardino-Balkarian State University n.a. Kh.M. Berbekov, Nalchik, Russia
To date, there are at least 6 national and international guidelines for the management of endocrine complications associated with the use of immune checkpoint inhibitors (ICPIs). This article is a summary of the latest guidelines developed by a number of scientists on behalf of the European Society of Endocrinology (ESE). The article presents possible endocrine complications during therapy with anti-CTLA-4, anti-PD-1, anti-PD-L1 drugs and combination treatment with ipilimumab and nivolumab. Combination treatment with ICPIs with chemotherapy or targeted therapy is not discussed in the guidelines and article.
Keywords: ICPI-induced diabetes mellitus, hypophysitis, thyroid dysfunction, immune checkpoint inhibitors, endocrinopathies
About the Autors
Corresponding author: Inessa B. Zhurtova, Dr. Sci. (Med.), Professor at the Department of Faculty Therapy, Medical Academy, Kabardino-Balkarian State University named after Kh.M. Berbekov, Nalchik, Russia; zhin07@mail.ru
Similar Articles
